Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 21 of 21 publications.

Fortuny J, Plana E, Kaye JA. Serum lipid trajectories in the years before a lymphoma diagnosis. Leuk Lymphoma. 2022 Feb;63(2):291-303. doi: 10.1080/10428194.2021.1992618

Goyal RK, Jain P, Nagar SP, Le H, Kabadi SM, Davis K, Kaye JA, Du XL, Wang M. Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma. Leuk Lymphoma. 2021 Jun;62(6):1325-34. doi: 10.1080/10428194.2021.1919662

Ramasamy K, Dhanasiri S, Thom H, Buchanan V, Robinson S, D'Souza VK, Weisel K. Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis. Leuk Lymphoma. 2020 Mar;61(3):668-79. doi: 10.1080/10428194.2019.1683736

Standaert B, Van Vlaenderen I, Van Bellinghen LA, Talbird SE, Hicks K, Carrico J, Buck PO. Constrained optimization for the selection of influenza vaccines to maximize the population benefit: a demonstration project. Appl Health Econ Health Policy. 2019 Nov 22. doi: 10.1007/s40258-019-00534-y

Goyal RK, Nagar SP, Kabadi SM, Kaye JA, Seal B, Mato AR. Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United States. Leuk Lymphoma. 2019 Apr;60(4):955-63. doi: 10.1080/10428194.2018.1509320

Turner EE, Jenks M, McCool C, Marshall C, Millar L, Wood H, Peel A, Craig J, Sims AJ. The Memokath-051 stent for the treatment of ureteric obstruction: a NICE medical technology guidance. Appl Health Econ Health Policy. 2018 Aug;16(4):445-64. doi: 10.1007/s40258-018-0389-3

Evans JM, Cleves A, Morgan H, Millar L, Carolan-Rees G. ENDURALIFE-powered cardiac resynchronisation therapy defibrillator devices for treating heart failure: a NICE Medical Technology Guidance. Appl Health Econ Health Policy. 2018 Apr;16(2):177-86. doi: 10.1007/s40258-017-0354-6.

Wong-Sefidan I, Byrtek M, Zhou X, Friedberg JW, Flowers CR, Zelenetz AD, Dawson KL, Reid E. Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice. Leuk Lymphoma. 2017 Apr;58(4):809-15.

Nastoupil LJ, Sinha R, Byrtek M, Ziemiecki R, Taylor M, Friedberg JW, Koff JL, Link BK, Cerhan JR, Dawson KL, Flowers CR. Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States. Leuk Lymphoma. 2015 May;56(5):1295-302. doi: 10.3109/10428194.2014.953144

Barbieri M, Weatherly HL, Ara R, Basarir H, Sculpher M, Adams R, Ahmed H, Coles C, Guerrero-Urbano T, Nutting C, Powell M. What is the quality of economic evaluations of non-drug therapies? A systematic review and critical appraisal of economic evaluations of radiotherapy for cancer. Appl Health Econ Health Policy. 2014 Oct;12(5):497-510. doi: 10.1007/s40258-014-0115-8

Karve S, Markowitz M, Fu DJ, Lindenmayer JP, Wang CC, Candrilli SD, Alphs L. Assessing medication adherence and healthcare utilization and cost patterns among hospital-discharged patients with schizoaffective disorder. Appl Health Econ Health Policy. 2014 Jun;12(3):335-46.

Meyers J, Yu Y, Kaye JA, Davis KL. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs. Appl Health Econ Health Policy. 2013 May 16;11(3):275-86. doi: 10.1007/s40258-013-0032-2

Karve S, Misurski D, Herrera-Taracena G, Davis KL. Annual all-cause healthcare costs among influenza patients with and without influenza-related complications: analysis of a United States managed care database. Appl Health Econ Health Policy. 2013 Apr 1;11(2):119-28.

Kattan MW, Earnshaw SR, McDade CL, Black LK, Andriole GL. Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE clinical trial. Appl Health Econ Health Policy. 2011 Sep 1;9(5):305-15.

Davis KL, Bell TJ, Miller JM, Misurski DA, Bapat B. Hospital costs, length of stay and mortality associated with childhood, adolescent and young adult meningococcal disease in the US. Appl Health Econ Health Policy. 2011 May 1;9(3):197-207.

Earnshaw SR, Graham J, Oleen-Burkey M, Castelli-Haley J, Johnson K. Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis. Appl Health Econ Health Policy. 2009 Jun 1;7(2):91-108.

Davis KL, Mitra D, Kotapati S, Ibrahim R, Wolchok JD. Direct economic burden of high risk and metastatic melanoma: evidence from the SEER-Medicare linked database. Appl Health Econ Health Policy. 2009;7(1):31-41.

Chang JE, Medlin SC, Kahl BS, Longo WL, Williams EC, Lionberger J, Kim K, Kim J, Esterberg E, Juckett MB. Augmented and standard Berlin-Frankfurt-Munster chemotherapy for treatment of adult acute lymphoblastic leukemia. Leuk Lymphoma. 2008 Dec;49(12):2298-307. doi: 10.1080/10428190802517732

Manga N, Duffy JC, Rowe PH, Cronin MTD. Structure-based methods for the prediction of the dominant P450 enzyme in human drug biotransformation: consideration of CYP3A4, CYP2C9, CYP2D6. SAR QSAR Environ Res. 2005 Feb;16(1-2):43-61.

Rothman KJ. Interaction and evolution in epidemiology. Soz Praventivmed. 2004 Apr 1;49(2):105-6.

Cronin MT, Dearden JC, Duffy JC, Edwards R, Manga N, Worth AP, Worgan AD. The importance of hydrophobicity and electrophilicity descriptors in mechanistically-based QSARs for toxicological endpoints. SAR QSAR Environ Res. 2002 Mar;13(1):167-76.